Actively Recruiting
Effect of Recombinant Human Brain Natriuretic Peptide on Ventricular Remodeling and Cardiac Function in Patients With Acute Anterior Myocardial Infraction Undergoing Percutaneous Coronary Intervention
Led by The First Affiliated Hospital with Nanjing Medical University · Updated on 2024-06-18
100
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is designed to evaluate the efficacy and safety of Recombinant Human Brain Natriuretic Peptide (rhBNP) in improving ventricular remodeling and cardiac function after acute anterior myocardial infarction undergoing percutaneous coronary intervention. 100 patients with acute anterior myocardial infarction after primary Percutaneous Coronary Intervention (pPCI) are randomly assigned 1:1 to rhBNP group(n=50) and control group(n=50) with follow-up of 24 weeks. Both groups are treated with standard therapy of AAMI, with the rhBNP group intravenous dripping rhBNP after pPCI for 3 days and the control group treated with placebo at the same time. The primary endpoint is the change in N terminal pro-B-type natriuretic peptide（NT-proBNP ）and cardiac troponin T(cTnT) level.The secondary endpoint is the change in 24-week echocardiographic including left ventricle ejection fraction (LVEF) , left ventricular end-diastolic volume index (LVEDVI) and left ventricular end-systolic volume index (LVESVI), arrhythmia and cardiovascular events (death, cardiac arrest or cardiopulmonary resuscitation, hospitalization due to heart failure or angina pectoris).
CONDITIONS
Official Title
Effect of Recombinant Human Brain Natriuretic Peptide on Ventricular Remodeling and Cardiac Function in Patients With Acute Anterior Myocardial Infraction Undergoing Percutaneous Coronary Intervention
Who Can Participate
Eligibility Criteria
You may qualify if you...
- First acute anterior myocardial infarction within 12 hours, or ongoing ischemic symptoms if more than 12 hours
- Age between 18 and 75 years, any gender
- Acute anterior myocardial infarction patients undergoing emergency PCI within the effective time window
- Successful blood flow restoration after interventional therapy (TIMI = 3)
- Able to understand and sign informed consent
You will not qualify if you...
- History of coronary artery bypass grafting
- Cardiogenic shock
- Systolic blood pressure 90 mmHg or less after vasopressor treatment
- Mechanical complications such as ventricular septal perforation or mitral chordae rupture
- Suspected aortic dissection
- Severe liver or kidney dysfunction
- Allergy or intolerance to rhBNP
- Chronic renal insufficiency requiring long-term dialysis
- Use of diuretics during the screening period
- Pregnant or lactating women
- Heart diseases unsuitable for vasodilators, including severe valve stenosis, restrictive cardiomyopathy, or restrictive pericarditis
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Actively Recruiting
Research Team
L
LianSheng Wang
CONTACT
Y
Yang Yang
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here